Assessment of vitamin D deficiency and COVID-19 diagnosis in patients with breast or prostate cancer using electronic medical records
risk of case, 35.1% lower, OR 0.65, p = 0.01, high D levels 13,903, low D levels 2,384, adjusted per study, inverted to make OR<1 favor high D levels, breast cancer patients, logistic regression, RR approximated with OR.
|
risk of case, 32.4% lower, OR 0.68, p = 0.045, high D levels 13,601, low D levels 1,318, adjusted per study, inverted to make OR<1 favor high D levels, prostate cancer patients, logistic regression, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Galaznik et al., 28 May 2021, retrospective, USA, preprint, 6 authors.
Abstract: Assessment of Vitamin D deficiency and COVID-19 diagnosis in patients with breast or
prostate cancer using Electronic Medical Records
Aaron Galaznik, MD MBA1 | Emelly Rusli, MPH1 | Vicki Wing, MS1 | Rahul Jain, PhD1 | Sheila Diamond, MS CGC1 | David Fajgenbaum, MD MBA MSc FCPP2
1 Medidata Acorn AI, a Dassault Systèmes company, New York, NY, 10014 | 2 Castleman Disease Collaborative Network and the University of Pennsylvania, Philadelphia, PA, 19104
RESULTS
BACKGROUND
BACKGROUND
•
•
While patients with cancer are known to be at increased risk
of infection in part due to the immunocompromising nature of
cancer treatments, recent data indicate a particularly high
risk for COVID-19 infection and poor outcomes. 1
•
Our study suggests
potentially vulnerable
populations, such as breast
and prostate cancer
patients, may have an
elevated risk of
COVID-19 infection if
vitamin D deficient.
Vitamin D deficiency has been previously reported in two
leading causes of cancer deaths: breast and prostate. 4
•
In this study, we performed a retrospective cohort analysis on
nationally representative electronic medical records (EMR) to
assess whether vitamin D deficiency affects risk of COVID19 among these patients.
Vitamin D may play an important role in COVID-19. A recent
study demonstrated vitamin D deficiency may increase risk of
COVID-19 infection, and a small randomized controlled trial
in Spain reported significant improvement in mortality among
hospitalized patients treated with calcifediol. 2,3
METHODS
Figure 1. Study Timeline
•
A total of 16,287 breast cancer and 14,919 prostate cancer patients were included in the study. (Figure 2)
Table 1. Patient Demographic and Clinical Characteristics
Breast Cancer
TOTAL (N = 16,287)
Patient Characteristics
N/Mean
%/SD
N/Mean
%/SD
68.9
11.3
73.6
8.5
<70 years (n, %)
7,962
48.9%
4,625
31.0%
70-79 years (n, %)
5,368
33.0%
6,499
43.6%
80+ years (n, %)
2,957
18.2%
3,795
25.4%
16,287
100.0%
0
0.0%
0
13,805
2,102
305
16
49
10
0.0%
84.8%
12.9%
1.9%
0.1%
0.3%
0.1%
14,919
12,390
2,405
89
12
22
1
100.0%
83.1%
16.1%
0.6%
0.1%
0.1%
0.0%
2,384
14.6%
1,318
8.8%
1.1
1.5
1.4
1.7
Congestive heart failure (n, %)
1,075
6.60%
1,483
9.94%
Obesity (n, %)
5,036
30.9%
4,627
31.0%
Diabetes mellitus (n, %)
3,327
20.4%
3,897
26.1%
356
2.2%
303
2.0%
1,730
10.6%
2,371
15.9%
Age (Mean, SD)
Sex (n, %)
Female
Male
White
Race (n, %)
Black
Asian
Native Hawaiian/Pacific Islander
American Indian or Alaska Native
Missing
Vitamin D deficient (n, %)
Comorbid
Conditions
Quan Charlson Comorbidity Index (Mean, SD)
Liver disease (n, %)
Figure 2. Patient Attrition
Patient with ≥ 1 encounter
between 3/1/2018 and
3/1/2019, and after 3/1/2020
(index date)
Age ≥ 18 and non-missing sex
and race
n = 1,630,384 (52.8%)
•
•
•
Patients with breast (female) or prostate (male) cancer
were identified between 3/1/2018 and 3/1/2020 from
Healthjump EMR data provided pro-bono by the COVID-19
Research Database.5
Logistic regressions, adjusted for baseline demographic
and clinical characteristics assessed in the 12 months prior
to 3/1/2020, were conducted to estimate the effect of
•
•
The average age was 68.9 years in the breast cancer cohort
and 73.6 years in the prostate cancer cohort.
(Table 1)
•
Approximately 15% of the breast cancer cohort and 9% of
the prostate cancer cohort had vitamin D deficiency.
•
The most common comorbid conditions were obesity
(approximately a third..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit